| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2590 | 2010 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 713 | 2009 |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ... Clinical Cancer Research 9 (8), 2893-2897, 2003 | 473 | 2003 |
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ... Clinical Cancer Research 8 (5), 1080-1084, 2002 | 362 | 2002 |
| Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients C Raimondi, A Gradilone, G Naso, B Vincenzi, A Petracca, C Nicolazzo, ... Breast cancer research and treatment 130, 449-455, 2011 | 318 | 2011 |
| High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 311 | 2008 |
| Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini Journal of clinical pathology 57 (6), 591-597, 2004 | 302 | 2004 |
| Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples M Russano, A Napolitano, G Ribelli, M Iuliani, S Simonetti, F Citarella, ... Journal of Experimental & Clinical Cancer Research 39, 1-13, 2020 | 237 | 2020 |
| Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? G Badalamenti, D Fanale, L Incorvaia, N Barraco, A Listi, R Maragliano, ... Cellular immunology 343, 103753, 2019 | 231 | 2019 |
| Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ... Annals of Oncology 23 (9), 2313-2318, 2012 | 231 | 2012 |
| Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in … D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ... Clinical Cancer Research 13 (15), 4482-4486, 2007 | 222 | 2007 |
| The antineoplastic role of bisphosphonates: from basic research to clinical evidence D Santini, UV Gentilucci, B Vincenzi, A Picardi, F Vasaturo, A La Cesa, ... Annals of Oncology 14 (10), 1468-1476, 2003 | 220 | 2003 |
| Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ... The oncologist 15 (1), 85-92, 2010 | 214 | 2010 |
| Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ... PloS one 6 (4), e19234, 2011 | 211 | 2011 |
| Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance R Addeo, M Caraglia, S Bellini, A Abbruzzese, B Vincenzi, L Montella, ... Journal of clinical oncology 28 (4), 543-548, 2010 | 205 | 2010 |
| Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study P Sperone, A Ferrero, F Daffara, A Priola, B Zaggia, M Volante, D Santini, ... Endocrine-related cancer 17 (2), 445-453, 2010 | 200 | 2010 |
| Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ... Journal of Clinical Oncology 24 (12), 1883-1891, 2006 | 197 | 2006 |
| Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ... Journal of interferon & cytokine research 25 (3), 144-151, 2005 | 193 | 2005 |
| Fever after zoledronic acid administration is due to increase in TNF-α and IL-6 G Dicuonzo, B Vincenzi, D Santini, G Avvisati, L Rocci, F Battistoni, ... Journal of interferon & cytokine research 23 (11), 649-654, 2003 | 189 | 2003 |
| Cetuximab: from bench to bedside B Vincenzi, A Zoccoli, F Pantano, O Venditti, S Galluzzo Current cancer drug targets 10 (1), 80, 2010 | 177 | 2010 |